| Category | Clinical Skincare |
| Founded | 2019 |
| Headquarters | Shanghai |
| Listing | Private (emerging domestic brand) |
| Latest revenue | No audited financials disclosed |
| Hero SKUs | Pentacyclic Serum |
Brand History
Founded around 2019, Pibo grew up in the ingredient-savvy generation. Its starting point was not a hero SKU but a laboratory posture: transparent concentrations, tolerance-building plans, and detail pages explaining what each ingredient does and its risks. The pentacyclic serum, salicylic line and retinol line form the skeleton.
Unlike most emerging brands that chase a hit first, Pibo's path was trust before range: science content on Zhihu and Bilibili trained users into semi-literate skincare consumers, then stepped them up to higher concentrations. Prices sit at RMB 80-200 in the mainstream of domestic clinical skincare. As the category saturates, Pibo's problem is the opposite of a conglomerate's — it lacks not reputation but the channels and capacity to scale that reputation into revenue.
Hero Products
Three-Year Financials
Neither the brand nor its parent publishes audited annual financials; no estimates are provided.
Brand-level：Revenue is not public. Press reports place the brand near the top of Tmall and Douyin clinical skincare on salicylic-acid and retinol SKUs, at RMB 80-200 price points.
Source：Brand materials; trade press; public e-commerce rankings
Company Coverage
- 2025-11Clinical skincare saturates
Leading domestic brands cut both concentration claims and prices.
Source：Trade media - 2025-07Tolerance education as a selling point
Step-by-step plans become bundled product routines.
Source：Brand updates - 2025-04First offline store
A skin-management experience store marks its offline entry.
Source：Press reports
Editor's note: Pibo represents the methodology school of Chinese clinical skincare — selling a usage plan, not a bottle. The ceiling is scale: a method cannot be amplified in one livestream like a hero SKU can. If it productises the tolerance plan into bundles and subscriptions, trust turns into repurchase rate — its key differentiation.